

## **Updated COVID-19 vaccine recommendations**

**Additional Dose (3rd Dose)** : A subsequent FULL vaccine dose to people who likely did not mount a protective immune response after primary vaccination in order to optimize vaccine induced protection

- Pfizer additional dose: 0.3ml
- Moderna additional dose: 0.5ml

**Booster Dose:** a subsequent dose of vaccine administered when the initial sufficient immune response to a primary vaccine series is likely to have waned over time. Dose dependent on individual manufacturer

- Pfizer **booster** dose: 0.3ml
- Moderna **booster** dose: **0.25ml**
- J&J **booster** dose: 0.5ml

\*Booster doses can be mixed or matched regardless of initial series manufacturer

**If received Janssen primary dose – Administer any COVID-19 vaccine booster dose  $\geq 2$  months after the initial Janssen dose, regardless of immune status**

- Pfizer **booster** dose: 0.3ml
- Moderna **booster** dose: 0.25ml
- J&J **booster** dose: 0.5ml

**For patients who are not immunocompromised, and have received a 2-dose primary series of Pfizer/Moderna or 1-dose J&J, they are eligible to receive a booster dose of any vaccine**

- Pfizer **booster** dose: 0.3ml
- Moderna **booster** dose: **0.25ml**
- J&J **booster** dose: 0.5ml

## **Recommendations for Immunocompromised patients**

**Moderately and severely immunocompromised people are defined as:**

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e.,  $\geq 20$ mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory

**\*Immunocompromised inclusion criteria do not include older adults based on age alone**

## Instructions for immunocompromised populations:

### If received primary series (2 doses)

– Administer **additional dose**  $\geq 28$  days after second dose

- Pfizer additional dose: 0.3ml
- Moderna additional dose: 0.5ml

– Then, Administer any COVID-19 vaccine booster dose  $\geq 6$  months after the additional third dose

- Pfizer **booster** dose: 0.3ml
- Moderna **booster** dose: 0.25ml

### If received Janssen primary dose – Administer any COVID-19 vaccine booster dose $\geq 2$ months after the initial Janssen dose

- Pfizer **booster** dose: 0.3ml
- Moderna **booster** dose: 0.25ml
- J&J **booster** dose: 0.5ml

**Instructions for immunocompromised patients who received a 2-dose primary series:**

Is the patient moderately to severely immunocompromised?

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory
- **\*immunosuppressed inclusion criteria does not include older adults solely based on age**

Which Primary Series has the patient completed

YES

Moderna, 2 doses

Pfizer, 2 doses

AFTER 28 DAYS

Give additional dose of Moderna 0.5ml

Give additional dose of Pfizer 0.3ml

6 MONTHS AFTER 3rd DOSE

Give Moderna booster of 0.25ml

Give Pfizer booster of 0.3ml

**\*\*These patients will end up receiving a total of 4 doses**

NO

For patients who are not moderately to severely immunocompromised, and have completed the primary series, follow the **booster dose** recommendations.

Primary Series Moderna or Pfizer completed?

YES

Has it been 6 months since completion of primary series?

YES

Give booster dose of Moderna 0.25ml

Give booster dose of Pfizer 0.3ml

NO

Wait until it has been 6 months since primary series completion

NO

Administer any COVID-19 vaccine booster dose ≥2 months after initial Janssen dose

## Commonly Prescribed Immunosuppressive Drugs

Drug Class	For treatment of	Brand (generic)
High Dose Corticosteroids	Various disease states	>= 20mg of prednisone or equivalent per day  *see below chart for steroid equivalency chart
TNF-alpha inhibitors	Rheumatoid Arthritis, Psoriatic Arthritis	Enbrel (etanercept) Humira (adalimumab) Remicade (infliximab) Simponi (golimumab) Cimiza (certolizumab)
Alkylating Agents	Cancer treatment	<u>Nitrogen Mustards:</u> Bendamustine Chlorambucil Cyclophosphamide Ifosfamide Mechlorethamine  <u>Other:</u> Carmustine Lomustine Streptozocin Busulfan Dacarbazine Temozolomide Altretamine thiotepa
Antimetabolites	Cancer Chemotherapy	Methotrexate 6-mercaptopurine 6-thioguanine Azathioprine Fludarabine  5-Fluorouracil Capecitabine Cytarabine
Calcineurin Inhibitors	Postoperative Immunosuppression	Prograf* (tacrolimus) Neoral* (cyclosporine)
Selective Immunosuppressants	Organ Transplant rejection prevention, cancer, autoimmune diseases	basiliximab Omalizumab Fingolimod Dimethyl fumarate

		Abatacept Everolimus Mycophenolic acid Siponimod Thymoglobulin (anti-thymocyte globulin) Sirolimus Belatacept tacrolimus
--	--	---

Corticosteroid Equivalency Chart

<b>Compound</b>	<b>Equivalent Dose</b>
Cortisone	100 mg
Hydrocortisone	80 mg
Prednisone	20 mg
Prednisolone	20 mg
Triamcinolone	16 mg
Methylprednisolone	16 mg
Betamethasone	3.2 mg
Dexamethasone	3.2 mg
Fludrocortisone	-

SOURCE: [https://emergency.cdc.gov/coca/ppt/2021/102621\\_slide.pdf](https://emergency.cdc.gov/coca/ppt/2021/102621_slide.pdf)

Reddy, Sujan MD MSc. "What CLinicians need to know about the recent updates to CDC's recommendations for COVID-19 boosters" Slide Deck. CDC: Vaccine Task Force, COVID-19 Response. Centers for Disease Control and Prevention. Presented Oct 26, 2021. Accessed Oct 27 2021.

[https://emergency.cdc.gov/coca/ppt/2021/102621\\_slide.pdf](https://emergency.cdc.gov/coca/ppt/2021/102621_slide.pdf)

